FISHAWACK-HEALTH
Fishawack Health , the global healthcare communications agency, announces the acquisition of Skysis , a boutique consulting firm providing integrated market access and commercial strategy solutions based in the US.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200408005692/en/
Skysis expertise bolsters Fishawack Health’s impressive consulting capabilities. The company brings with it the ability to connect interdependencies across healthcare professional (HCP), payer, channel, and patient stakeholders. It is the first acquisition with Fishawack Health’s new investor, Bridgepoint.
Oliver Dennis , Fishawack Health co-founder and CEO, said: “In partnering with Bridgepoint, we have made a step-change in our ambition. We’re delighted today to add Skysis to the group. They bring strategy and market access across the entire commercial life cycle, making them an important addition to our strategic consulting capabilities.”
Fred Bassett , Head of Consulting for Fishawack Health, added: “Skysis provides strategy and execution across every stage of the commercial life cycle. The company’s expertise bolsters Fishawack Health’s strong strategic consulting team, which includes analysts, researchers, commercial consultants, market access and customer experience specialists, and boasts a network of Physician Expert Partnerships.”
Providing further detail, Dan Twibell , Managing Director of Skysis, explained: “We wanted to partner with a group that could help us scale our business, offer more solutions to our clients and that our team would be excited to join.”
Dawn Rich , Managing Director of Skysis, said: “Our team is thrilled to be joining Fishawack Health. Our core capabilities match perfectly with the key services of the wider consulting capability.”
Fairmount Partners, a leading investment bank focused on pharmaceutical services businesses, introduced the parties identifying that Skysis’ four core practice areas – market access, new product planning /launch excellence, market insights, brand management and engagement – were a perfect match with Fishawack Health’s capabilities.
Established in 2001, Fishawack Health has become one of the largest independent healthcare communications organisations in the world. It has 14 offices across Europe and the US, and a highly skilled workforce of 850 employees. It serves more than 100 customers across 300 different drug compounds, including the top 20 global pharmaceutical companies and a range of innovative biotech and medical device companies.
Its three areas of specialism – strategic consulting and market access, medical communications, and commercial and creative execution – are underpinned by shared world-class resources. This includes digital expertise, insight, data analytics and visualisation, and media and production capabilities. These capabilities work independently or combine seamlessly as one unit, complete with teams tailored to the client’s individual needs and challenges.
Fishawack Health’s strategic and scientific focus makes it ideally placed to solve complex brand, portfolio, and enterprise-level challenges for its clients.
With experience across every major therapeutic category, Fishawack Health understands what it takes to improve patient outcomes and drive business success for its clients. The company will continue to add new capabilities designed to solve its clients’ critical medical and commercial challenges in an integrated and seamless way.
About Fishawack Health
Fishawack Health is an independent, full-service, global healthcare communications group with over 850 medical experts, marketing professionals, and strategic specialists. The organisation has three areas of specialism that work independently or as a single united team – strategic consulting and market access, medical communications, and commercial/creative execution.
About Skysis
Skysis is a boutique consulting firm that provides integrated commercial solutions to the biopharmaceutical industry. The organisation leverages their deep industry experience to generate insights and approaches that address their clients’ unique commercial needs.
Advisers involved in this transaction included:
KPMG Manchester acted on behalf of Fishawack Health for corporate finance and financial & tax due diligence; Addleshaw Goddard, Manchester and Sheppard Mullin, San Diego provided legal support. KPMG, Fairmount Partners, a leading investment bank focused on pharmaceutical services businesses, introduced the parties and acted as financial advisor to Skysis. Ulber & Berne LLP provided legal support.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200408005692/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom